MOTS-c 10mg

MOTS-c 10 mg Dragon Pharma — Overview

MOTS-c 10 mg Dragon Pharma is a lyophilized injectable peptide derived from the mitochondrial genome — specifically encoded within the 12S rRNA gene of mitochondrial DNA. It is a 21-amino-acid mitochondria-derived peptide (MDP) that functions as an endogenous regulator of cellular energy metabolism, activating the AMPK pathway through a mitochondria-to-nucleus signaling cascade. MOTS-c has no androgenic activity, no estrogenic activity, and no effect on the HPG axis. It requires no PCT.

The compound is in a distinct class from SARMs, AAS, or GH secretagogues. Its primary actions center on metabolic regulation: improving insulin sensitivity, supporting fat oxidation, reducing systemic inflammation, and replicating at the cellular level some of the metabolic adaptations triggered by aerobic exercise. Research has also identified MOTS-c as a circulating exercise-induced signal — plasma levels rise with physical exertion — positioning it as a genuine exercise mimetic rather than simply a metabolic drug. This page covers the mitochondrial signaling mechanism, practical metabolic effects, how MOTS-c compares to AICAR and AOD-9604, and combination use with other peptides available at Steroid Warehouse.

About the Compound: MOTS-c

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a 21-amino-acid peptide encoded within the mitochondrial 12S ribosomal RNA gene — an unusual location, as most peptide hormones are encoded in nuclear DNA. Its discovery in 2015 established a new category of signaling molecules: mitochondria-derived peptides (MDPs) that communicate metabolic status from mitochondria to the rest of the cell and to distant tissues via the bloodstream.

The mechanism operates through mitochondrial metabolism. MOTS-c activity leads to accumulation of AICAR (an AMP analog) within mitochondria, which in turn activates AMPK (AMP-activated protein kinase) — the central cellular energy sensor. AMPK activation produces a cascade of metabolic adaptations: increased glucose uptake in skeletal muscle, enhanced fat oxidation, inhibition of anabolic processes that consume ATP without producing energy, reduction of mitochondrial reactive oxygen species, and upregulation of mitochondrial biogenesis. This profile closely mirrors the acute metabolic response to aerobic exercise, which is why MOTS-c is classified as an exercise mimetic alongside compounds like AICAR.

Notably, MOTS-c is not simply a synthetic pharmaceutical — it is an endogenous peptide that rises naturally in human plasma after physical exercise and declines with age. The age-related decline in circulating MOTS-c is proposed as a contributing factor to age-associated insulin resistance, metabolic dysfunction, and reduced exercise capacity. Exogenous MOTS-c supplementation is designed to restore or augment this endogenous signal.

What MOTS-c Does

• AMPK activation and improved insulin sensitivity — AMPK is the master regulator of cellular energy balance; its activation by MOTS-c increases GLUT4 translocation to the cell membrane in skeletal muscle, allowing more efficient glucose uptake without requiring increased insulin secretion; this directly reduces insulin resistance; preclinical data show MOTS-c administration reverses diet-induced insulin resistance in animal models; in practical terms, this means improved nutrient partitioning — ingested carbohydrates are preferentially directed toward muscle glycogen replenishment rather than adipose storage
• Enhanced fat oxidation and body composition support — AMPK activation simultaneously reduces fatty acid synthesis and increases beta-oxidation (fat burning) in mitochondria; this shifts substrate utilization toward fat during both exercise and rest; MOTS-c does not cause acute fat loss in the manner of stimulants or thyroid agents, but over extended use it biases the metabolic machinery toward fat as a fuel source; the effect is more pronounced during physical activity, which is why MOTS-c is most productive when combined with consistent training
• Exercise mimetic and physical performance support — endogenous MOTS-c rises measurably in human plasma during aerobic exercise; exogenous administration replicates some of the metabolic adaptations that exercise training produces at the mitochondrial level, including improvements in mitochondrial efficiency, oxidative capacity, and cellular stress resilience; this makes MOTS-c relevant both as a standalone metabolic compound and as a complement to active training protocols
• Anti-inflammatory and oxidative stress reduction — MOTS-c reduces mitochondrial reactive oxygen species (ROS) production and modulates inflammatory signaling pathways; this anti-inflammatory action is particularly relevant during high-volume training phases, metabolic stress periods, or AAS cycles where systemic inflammation is elevated; the mechanism is distinct from standard anti-inflammatory compounds and operates at the mitochondrial level
• Age-related metabolic support — circulating MOTS-c declines with age in a pattern parallel to the age-related decline in exercise capacity and insulin sensitivity; research positions MOTS-c as one of the mechanisms through which exercise preserves metabolic health across the lifespan; for older users or those with reduced metabolic flexibility, MOTS-c supplementation may restore part of this endogenous signaling loss

Who It's For

• Users targeting insulin sensitivity, nutrient partitioning, and body recomposition — MOTS-c is most directly useful for users who want to improve how their body handles glucose and partitions nutrients: preferring muscle over fat during caloric surplus, improving recovery between training sessions, and supporting fat oxidation during training; this profile makes it relevant for anyone running a body recomposition protocol, managing the metabolic stress of an AAS or SARM cycle, or seeking to counteract the glucose/insulin side effects that can accompany compounds like MK-677
• Users on high-dose AAS cycles where insulin resistance and metabolic stress are elevated — androgenic compounds at supraphysiological doses can impair insulin sensitivity and increase systemic inflammation; MOTS-c's AMPK-activating and insulin-sensitizing effects directly counter these metabolic side effects; adding MOTS-c as a cycle support component addresses a metabolic dimension that most standard cycle support products do not target
• Older or metabolically compromised users seeking exercise-derived metabolic benefits — because MOTS-c is a naturally declining endogenous peptide, its supplementation is particularly rational for users over 40 where the age-related drop in circulating MOTS-c contributes to metabolic stiffening; the exercise mimetic effect is relevant for users who cannot train at high volumes due to injury, age, or recovery constraints but want to preserve the metabolic adaptations that exercise produces
• Users who may not be the right fit for MOTS-c: users seeking acute, visible performance gains on a short 4–6 week cycle will not find those results with MOTS-c; the compound's effects are metabolic and cumulative, not the kind that show up dramatically on a training log within weeks; users primarily focused on muscle mass gain should note that MOTS-c does not directly drive hypertrophy and is better positioned as a metabolic support compound than as a primary anabolic agent

Context & Related Products

MOTS-c occupies a specific niche: mitochondria-driven AMPK activation via the folate-cycle → AICAR → AMPK pathway. Several other peptides and compounds available at Steroid Warehouse address related but distinct metabolic targets.

Combination protocols:

Side Effects & Management

References